The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Sivertseva S.A.

Medical and Sanitary unit «Neftyanik»

Chemakina D.S.

Central Clinical Hospital of the Russian Academy of Sciences

Spirin N.N.

Yaroslavl State Medical University

Bykova O.V.

Research and Clinical Centre of Pediatric Psychoneurology Moscow Department of Public Health;
Medical Institute of the Peoples' Friendship University of Russia

Guseva M.E.

Pirogov Russian National Research Medical University

Vaccination and multiple sclerosis at the present stage

Authors:

Boyko A.N., Sivertseva S.A., Chemakina D.S., Spirin N.N., Bykova O.V., Guseva M.E.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7‑2): 44‑48

DOI: 10.17116/jnevro202112107244

Read: 15381 times

Download PDF (RU)
Contact the author
Table of contents

VACCINATION AND MULTIPLE SCLEROSIS AT THE PRESENT STAGE
VACCINATION AND MULTIPLE SCLEROSIS AT THE PRESENT STAGE

To cite this article:

Boyko AN, Sivertseva SA, Chemakina DS, Spirin NN, Bykova OV, Guseva ME. Vaccination and multiple sclerosis at the present stage. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7‑2):44‑48. (In Russ.)
https://doi.org/10.17116/jnevro202112107244

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Coro­navirus infe­ction as a risk factor in occlusive-stenotic lesions of the brachiocephalic arte­ries. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):44-52
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
mRNA cancer vaccines: features of problems and collisions. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(1):3-16
SpO2/RR index in choosing the method for correction of acute respiratory failure in COVID-19 patients. Russian Journal of Anesthesiology and Reanimatology. 2025;(2):50-58
Post-Covid aortitis with cardiac invo­lvement: progressive aortic aneurysm combined with active myocarditis. Russian Journal of Archive of Pathology. 2025;(2):53-58
Prediction and prevention of burnout syndrome in health care professionals in high epidemic risk settings. Russian Journal of Preventive Medi­cine. 2025;(4):51-56
Impact of the COVID-19 epidemic on students’ health. Part II. Features of hemo­dynamics, vege­tative regu­lation, resu­lts of psychological and stress resi­stance testing among students depe­nding on the COVID-19 presence in their medi­cal history. Russian Journal of Preventive Medi­cine. 2025;(4):94-101
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21
Therapeutic pote­ntial of quercetin and its deri­vatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50
Abstract:

Immunization of the patients with autoimmune diseases is rising a lot of concerns. It was previously demonstrated that vaccination in MS patients was not associated with an increased risk of exacerbations. A personalized approach is needed to define the immunization schedule. A decision should be made based on the course of the disease and the treatment used. Multiple sclerosis is not an absolute contraindication to vaccination. Any authorized vaccine can be used in MS patients.

Keywords:

multiple sclerosis
autoimmune diseases
vaccination
COVID-19

Authors:

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Sivertseva S.A.

Medical and Sanitary unit «Neftyanik»

Chemakina D.S.

Central Clinical Hospital of the Russian Academy of Sciences

Spirin N.N.

Yaroslavl State Medical University

Bykova O.V.

Research and Clinical Centre of Pediatric Psychoneurology Moscow Department of Public Health;
Medical Institute of the Peoples' Friendship University of Russia

Guseva M.E.

Pirogov Russian National Research Medical University

Received:

24.05.2021

Accepted:

25.05.2021

Close metadata

References:

  1. Pazmino S, Boonen A, Stouten V, et al. Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial. Ann Rheum Dis. 2020;79(5):556-665.  https://doi.org/10.1136/annrheumdis-2019-216874
  2. Ghabri S, Binard A, Pers Y-M, et al. Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France. Value Heal. 2020;23(4):461-470.  https://doi.org/10.1016/j.jval.2019.12.003
  3. Katz P, Wan GJ, Daly P. et al. Patient-reported flare frequency is associated with diminished quality of life and family role functioning in systemic lupus erythematosus. Qual Life Res. 2020;29(12):3251-3261. https://doi.org/10.1007/s11136-020-02572-9
  4. Hovde Ø. Epidemiology and clinical course of Crohn’s disease: Results from observational studies. World J Gastroenterol. 2012;18(15):1723. https://doi.org/10.3748/wjg.v18.i15.1723
  5. Wang L, Wang F-S, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278(4):369-395.  https://doi.wiley.com/10.1111/joim.12395
  6. Li X, Thomsen H, Sundquist K. et al. Familial Risks between Pernicious Anemia and Other Autoimmune Diseases in the Population of Sweden. REGO M, editor. Autoimmune Dis [Internet]. 2021;2021:1-5.  https://doi.org/10.1155/2021/8815297
  7. Anaya J, Shoenfeld Y, Rojas-Villarraga A. et al., ed. Autoimmunity From Bench to Bedside. Bogota (Colombia): El Rosario University Press; 2013.
  8. Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: What is the evidence? Lancet. 2003;362(9396):1659-1666. https://doi.org/10.1016/S0140-6736(03)14802-7
  9. Goriely S, Goldman M. From Tolerance to Autoimmunity: Is There a Risk in Early Life Vaccination? J Comp Pathol. 2007;137:57-61.  https://doi.org/10.1016/j.jcpa.2007.04.013
  10. Willame C, Dodd C, van der Aa L, et al. Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project. Drug Saf. 2021;4:35-39.  https://doi.org/10.1007/s40264-020-01031-1
  11. Ministerstvo zdravoohranenija Rossijskoj Federacii. Methodological recommendations on identification, investigation and prevention of the adverse events following immunization. M. 2019. (In Russ.).
  12. World Health Organization. Global Advisory Committee on Vaccine Safety (GACVS). 2021 [cited 2021 Feb 8]. (In Russ.). https://www.who.int/vaccine_safety/committee/ru/
  13. Winkelmann A, Loebermann M, Reisinger EC, et al. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol. 2016;12(4):217-233.  https://doi.org/10.1038/nrneurol.2016.21
  14. Zrzavy T, Kollaritsch H, Rommer PS, et al. Vaccination in Multiple Sclerosis: Friend or Foe? Front Immunol. 2019;10:1883. https://doi.org/10.3389/fimmu.2019.01883
  15. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. Clin Infect Dis. 2014;58(3):44-100.  https://doi.org/10.1093/cid/cit684
  16. Farez MF, Correale J, Armstrong MJ, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Neurology. 2019;93(13):584-594.  https://doi.org/10.1212/WNL.0000000000008157
  17. The World Health Organisation. Table 1: WHO recommendations for routine immunization. Who. 2020;(September):1-11.  https://www.who.int/publications/m/item/table-1-who-recommendations-for-routine-immunization
  18. A letter of the Federal medical biological agency 20th August 2020 №32-024/634. About the directions on recommendations of the catch-up vaccination. (In Russ.).
  19. Briko NI, Feldblyum IV. The Modern Concept of Development of Vaccine Prevention in Russia. Epidemiology and Vaccinal Prevention. 2019;18(5):4-13. (In Russ.). https://doi.org/10.31631/2073-3046-2019-18-5-4-13
  20. Namazova-Baranova LS, Fedoseenko MV, Baranov AA. New Horizons of National Immunization Calendar. Current Pediatrics. 2019;18(1):13-30. (In Russ.). https://doi.org/10.15690/vsp.v18i1.1988
  21. Jakimovski D, Weinstock-Guttman B, Ramanathan M, et al. Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective. Vaccines. 2020;8(1):50.  https://doi.org/10.3390/vaccines8010050
  22. Marshall E. Immunology: A Shadow Falls on Hepatitis B Vaccination Effort. Science. 1998;281(5377):630-631.  https://doi.org/10.1126/science.281.5377.630
  23. Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the Risk of Relapse in Multiple Sclerosis. N Engl J Med. 2001;344(5):319-326.  https://doi.org/10.1056/nejm200102013440501
  24. Wiedermann U, Sitte HH, Burgmann H, et al. Impfungen bei Immundefekten/Immunsuppression — Expertenstatement und Empfehlungen. Wien Klin Wochenschr. 2016;128(S4):337-376.  https://doi.org/10.1007/s00508-016-1033-6
  25. Ross R, Dawood M, Cheang M, Nicolle LE. Antibody Response in Seropositive Multiple Sclerosis Patients Vaccinated with Attenuated Live Varicella Zoster Virus. Can J Infect Dis. 1996;7(5):303-306.  https://doi.org/10.1155/1996/417061
  26. Moriabadi NF, Niewiesk S, Kruse N, et al. Influenza vaccination in MS: Absence of T-cell response against white matter proteins. Neurology. 2001;56(7):938-943.  https://doi.org/10.1212/WNL.56.7.938
  27. Olberg HK, Cox RJ, Nostbakken JK, et al. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study. Mult Scler J. 2014;20(8):1074-1080. https://doi.org/10.1177/1352458513513970
  28. Olberg HK, Eide GE, Cox RJ, et al. Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. Eur J Neurol. 2018;25(3):527-534.  https://doi.org/10.1111/ene.13537
  29. Sirbu C, Florea A, Ghinescu M, et al. Vaccination in multiple sclerosis — Challenging practices (Review). Exp Ther Med. 2020;20(6):1-1.  https://doi.org/10.3892/etm.2020.9347
  30. McCarthy CL, Tuohy O, Compston DAS, et al. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology. 2013;81(10):872-876.  https://doi.org/10.1212/WNL.0b013e3182a35215
  31. Triplett J, Kermode AG, Corbett A, at al. Fingolimod and unusual HPV-associated lesions. Mult Scler J. 2019;25(11):1547-1550. https://doi.org/10.1177/1352458518807088
  32. Klotz L, Havla J, Schwab N, et al. Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord. 2019;12:175628641983657. https://doi.org/10.1177/1756286419836571
  33. Michailidou A, Trenz H-J, de Wilde P. Summary of Product of Characteristics. Lemtrada. EMA. 2019;145(5):67-172. 
  34. World Health Organization. Novel Coronavirus_Landscape_COVID-19. 2021. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
  35. National Multiple Sclerosis Society. COVID-19 Vaccine Guidance for People Living with MS. 2021. https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance
  36. MS Society Medical Advisers consensus statement on MS treatments and COVID-19 vaccines. 2021. https://www.mssociety.org.uk/what-we-do/news/ms-society-medical-advisers-release-consensus-statement-covid-19-vaccines
  37. Zheng C, Kar I, Chen CK, et al. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination. CNS Drugs [Internet]. 2020;34(9):879-896.  https://doi.org/10.1007/s40263-020-00756-y
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.